• 농약과학회지
• /
• 제12권3호
• /
• pp.207-214
• /
• 2008

내분비장애 추정물질의 분류를 위해 많은 시험법이 연구되고 있는데 추후 내분비장애 추정물질로 분류된 기등록 농약에 대한 자료요구 또는 신규 등록농약에 대한 등록기준의 추가 등을 고려하여 OECD와 EPA에서 권장하는 시험법을 확립하고자 본 연구를 수행하였다. 시험약제를 30일간 경구 투여하여 조사한 결과, alachlor 투여 수컷에서 25 mg/kg/day, 50 mg/kg/day에서 고환과 갑성선의 중량이 증가하였다. Alachlor 투여 암컷에서는 질의 중량이 25, 50 mg/kg/day에서 감소하였고 25 mg/kg/day에서 갑상선의 중량이 감소하였다. Alachlor 투여 암컷 25, 50 mg/kg/day에서 주요 갑상선 호르몬인 T4와 성호르몬 testosterone이 감소하였다. 따라서 pubertal assay 결과 alachlor는 갑상선 호르몬성 영향이 의심되었다. 시험세포를 이용한 시험 결과, 시험약제를 1 nM에서 1000 nM까지 처리하였을 때 음성대조군과 비교하여 alachlor는 100-134%의 갑상선 호르몬성 영향을 나타내었다. 따라서 세포를 이용한 시험에서는 alachlor에 의한 갑상선 호르몬성 영향이 나타나는 것으로 판단되었다. 항갑상선 호르몬성 영향 시험에서는 시험약제 100 nM과 T4의 혼합 처리시 alachlor는 항갑상선 호르몬성 영향은 나타나지 않았다.

• 한국발생생물학회지:발생과생식
• /
• 제14권3호
• /
• pp.199-205
• /
• 2010

A neurotoxin, 6-hydroxydopamine (6-OHDA) has been widely used to create animal model for Parkinson's disease (PD). The present study was undertaken to examine whether depletion of brain dopamine (DA) stores with 6-OHDA can make alteration in the activities of the testicular steroidogenesis in adult rats. Young adult male rats (3 months old) were received a single dose of 6-OHDA (200 ${\mu}g$ in 10 ${\mu}{\ell}$/animal) by intracerebroventricular (icv) injection, and sacrificed after two weeks. The mRNA levels of steroidogenesis-related enzymes were measured by qRT-PCRs. Serum testosterone levels were measured by radioimmunoassay. Single icv infusion of 6-OHDA significantly decreased the mRNA levels of CYP11A1 (control:6-OHDA group=$1:0.68{\pm}0.14$ AU, p<0.05), CYP17 (control:6-OHDA group=$1:0.72{\pm}0.13$ AU, p<0.05). There were no changes in the mRNA levels of $3{\beta}$-HSD (control:6-OHDA group=$1:0.84{\pm}0.08$ AU) and $17{\beta}$-HSD (control: 6-OHDA group=$1:0.63{\pm}0.20$ AU), though the levels tended to be decreased in the 6-OHDA treated group. Administration of 6-OHDA decreased significantly the mRNA level of StAR when compared to the level of saline-injected control animals (control:6-OHDA group=$1:0.72{\pm}0.08$ AU, p<0.05). Treatment with single dose of 6-OHDA remarkably lowered serum testosterone levels compared to the levels of control group (control:6-OHDA group=$0.72{\pm}0.24:0.13{\pm}0.03ng/m{\ell}$, p<0.05). Taken together with our previous study, the present study demonstrated that the activities of hypothalamus-pituitary-testis hormonal axis could be negatively affected by blockade of brain DA biosynthesis, and suggested the reduced reproductive potential might be resulted in the animals. More precise information on the testicular steroidogenic activities in PD patients and PD-like animals should be required prior to the generalization of the sex steroid hormone therapy to meet the highest standards for safety and efficacy.

• 한국식품영양과학회지
• /
• 제43권4호
• /
• pp.507-515
• /
• 2014

본 연구는 전립선암세포주인 LNCaP 세포주와 테스토스테론으로 유도된 전립선비대 백서모델에서 복분자 추출물의 전립선비대 억제 효과를 조사하였다. 첫째, 전립선암 세포주(LNCaP)에서 복분자 미숙과 추출물의 안드로겐 관련 전립선비대 유전자 억제 효과를 조사한 결과 미숙과 50% 에탄올 추출물은 안드로겐 수용체(AR)뿐만 아니라 전립선특이항원(PSA)과 5-알파 환원 효소 type 2(5AR2)의 발현을 가장 높게 억제하였다. 또한 LNCaP 세포에 DHT로 안드로겐 관련 유전자를 유도한 후 복분자 미숙과 50% 에탄올 추출물을 처리한 결과 AR과 PSA mRNA의 발현이 억제됨을 확인하였다. 둘째, 테스토스테론을 이용하여 전립선비대를 유도한 동물모델에서 복분자 미숙과 50% 에탄올 추출물을 6주간 투여한 후 전립선비대 개선 효과를 조사한 결과, 전립선비대유발군에 복분자 미숙과 추출물을 투여한 군에서 전립선 무게, 전립선 소포의 상피세포 두께 및 면적이 감소함을 확인할 수 있었고, 전립선비대 유발 호르몬인 DHT level이 감소함을 확인할 수 있었다.

• 대한한방내과학회지
• /
• 제30권2호
• /
• pp.355-364
• /
• 2009

Objectives : Benign prostatic hyperplasia (BPH) is one of the most common diseases among elderly men. Though medicines such as 5${\alpha}$-reductase inhibitor (finasteride) have recently been developed for treating BPH, their adverse effects and low efficacy should not be overlooked. Curcuma longa has a long history of use in traditional medicines of Asian countries. Many reports conclude the component curcumin in Curcuma lonfa, has the potential to treat various diseases including prostate cancer. In this study, we investigated the therapeutic effects and action mechanism of Curcuma longa with a BPH rat model. Methods : Sprague-Dawley rats were used with subcutaneous injection of testosterone after castration, which were histologically similar to human BPH. A total of 30 rats were equally divided into five groups: Group 1 served as control (sham-operated group): Group 2 was the model group: Group 3 and Group 4 animals were administered Curcuma longa at dose levels of 0.5g/kg and 1.0g/kg: Group 5 served as a positive control group and was treated with finasteride at a dose of 1 mg/kg. The drugs were administered orally once a day for 30 days consecutively. After 31 days, the prostates were removed, and analyzed for their prostatic weight and histological examination. Results : The oral Curcuma longa ingestion group showed statistically significant decreases in their prostatic weights compared with the BPH-induced group and the oral finasteride ingestion group (p<0.05). Curcuma longa is also very safe in liver and kidney up to a dose of lg/kg. Injected testosterone histologically led to prostatic hyperplasia in rats, but oral Curcuma longa ingestion decreased this change. Conclusions : These results suggest that Curcuma longa has a definite inhibitory effect on BPH and might be an alternative medicine for treatment and prevention of human BPH.

• 생약학회지
• /
• 제38권2호통권149호
• /
• pp.197-203
• /
• 2007

Benign prostatic hyperplasia (BPH) is one of the common disease in elderly men. Recently old-age population is increased and we are growing more and more interested in clinical importance of BPH. In this study, the effect of PLX, which was the mixture of tomato extract (including 2% of lycopene) and chitooligosaccharide, on prostatic cancer cell and testosterone-induced BPH in adult rats of the Sprague Dawley strain was determined. The cell viability was evaluated by MTT method using L929 and LNCaP cell line, pretreated with various concentrations of PLX. The expression of prostatic specific antigen (PSA) and 5${\alpha$}$-reductase genes were evaluated by realtime PCR using LNCaP cell line and compared various concentrations of PLX with 50 ${\mu}$M of finasteride. An experimental prostatic hyperplasia was induced in male Sprague Dawley rats by giving testosterone for 8 weeks. After 2 weeks from start of giving testosterone, PLX and finasteride were administered orally once a day. The results were analyzed with prostate weight per body weight at 8 weeks. Cell viability of L929 cell line decreased specifically at the concentration of 2000 ${\mu}$g/mf of PLX. The cytotoxicity of PLX to the LNCaP cell line was shown at above 500 ${\mu}$g/ml of PLX. The inhibitory effect of PLX to the expression of PSA and 5${\alpha$}$-reductase genes in LNCaP cell line increased with the concentration of PLX. In vivo study, the results of PLX and finasteride administered group were 3.75${\pm}$0.60 and 3.49${\pm}$0.49 prostate weight ${\times}10^3$/body weight, which were lower than the result of BPH induced group (4.74${\pm}$0.58). These results suggested that PLX may be an effective material in BPH by having the role of the 5a-reductase inhibitor.

• 한국발생생물학회지:발생과생식
• /
• 제18권3호
• /
• pp.145-152
• /
• 2014

This study was performed to investigate the effect of of transdermal testosterone gel (TTG) on controlled ovarian stimulation (COS) and IVF outcomes and ovarian morphology according to pretreatment duration in poor responders. A total of 120 women were recruited for this pilot study. They were randomized into control, 2 weeks, 3 weeks or 4 weeks TTG treatment groups. For three TTG treatment groups, 12.5 mg TTG was applied daily for 2 weeks, 3 weeks or 4 weeks in preceding period of study stimulation cycle. After 3 weeks of TTG pretreatment, significant increase of antral follicle count (AFC) and significant decreases of mean follicular diameter (MFD) and resistance index (RI) value of ovarian stromal artery were observed (p=0.026, p<0.001, p<0.01, respectively). The total dose of rhFSH administered for COS significantly decreased after 3 and 4 weeks TTG treatment both compared with control group (p<0.001, p<0.001). The numbers of oocytes retrieved and mature oocytes were significanty higher in 3 and 4 weeks TTG treatment groups than control group (p<0.001, p<0.001 in the number of oocytes retrieved; p<0.001, p<0.001 in the number of mature oocytes). The clinical pregnancy rate and live birth rate were increased only in 4 weeks TTG treatment group compared with control group (p=0.030 and p=0.042, respectively). These data demonstrated that TTG pretreatment for 3 to 4 weeks increases AFC and ovarian stromal blood flow, thereby potentially improving the ovarian response to COS and IVF outcome in poor responders undergoing IVF/ICSI.

• Journal of Yeungnam Medical Science
• /
• 제23권1호
• /
• pp.62-70
• /
• 2006

전립선비대증은 노인 남성에서 흔히 유발되는 질환이며, 노화가 진행될 수록 빈도가 높아지는 특징을 가진다. 이 질환의 원인은 전립선 기질세포의 과도한 증식으로 유발된다고 알려져 있지만 그 자세한 기전에 대해서는 잘 알려져 있지 않다. 전립선비대증에서 progesterone 수용체 양성 세포가 다른 전립선 종양에 비해서 많고, progesterone은 testosterone에서 DHT로 전환되는 것을 감소시키는 역할을 가진다고 알려졌다. 또한 남성 전립선 평활근의 과증식에 의한 질환이므로 평활근 세포의 증식과 관련성이 있다고 보고된 COX-2의 전립선비대증에 대한 영향에 대한 연구가 필요하다. 전립선 기질세포에 progesterone을 3일간 투여하여 배양한 경우 기질세포 증식은 차이가 없었다. Progesterone을 단독 또는 DHT와 같이 투여한 기질세포에서 남성호르몬 수용체 mRNA 발현은 비처리군과 비교하여 유의한 차이가 없었다. 또한 progesterone과 DHT 동시 투여에 의한 COX-2 mRNA 발현에도 차이가 없었다. 그러나 progesterone에 의한 남성호르몬 수용체와 COX-2 단백 발현에서는 대조군과 비교하여 유의하게 감소시켰다. 이상의 결과는 progesterone은 남성호르몬 수용체에 대해 전사 후 반응 (post-transcriptional response)에 효과를 나타내어 남성호르몬 수용체 발현을 감소시키는 작용은 가지며, COX-2 발현 억제효과를 나타내므로 전립선비대증의 치료에 이용될 수 있을 것으로 사료된다.

• 한국응용과학기술학회지
• /
• 제37권6호
• /
• pp.1646-1658
• /
• 2020

이 연구의 목적은 운동 후 수중회복방법의 차이가 성장호르몬, 테스토스테론, 혈중젖산농도, 심부담도, 통증의 변화를 알아보는 것이다. 저항운동 경력 6개월 이상인 남자 7명을 대상으로 집중 웨이트 트레이닝과 서킷 웨이트트레이닝을 1RM의 60%강도로 실시한 다음 회복방법으로 수중걷기회복과 수중앉기 회복을 진행하였다. 성장호르몬은 모든 운동형태와 회복방법에서 운동 후, 회복 후, 안정 시 순으로 높게 나타났으며, 테스토스테론은 운동 후, 회복 후, 안정 시 순으로 높았다. 혈중젖산농도는 모든 운동형태와 회복방법에서 운동 후, 회복 후, 안정 시 순으로 높았으며 집중저항운동 후 동적회복이 정적회복보다 낮았다. 심부담도는 모든 운동형태와 회복방법에서 운동 후, 회복 후, 안정 시 순으로 높았다. 근통증은 모든 운동형태와 회복방법에서 운동직후, 회복 후, 24시간, 48시간, 72시간 순으로 감소하였다. 물속 환경에서도 동적회복이 정적회복보다 근피로 개선에 효과가 있는 것으로 사료된다.

• 핵의학기술
• /
• 제27권1호
• /
• pp.55-61
• /
• 2023

Purpose In this study, the monthly population distribution was calculated for statistical verification of 10 tests (CA19-9, CA15-3, testosterone, PTH, calcitonin, AFP, CEA, CA72-4, PSA, estradiol) with changed reagents, and the trend of change By comparing and analyzing the results, we want to verify the accuracy of the results and improve the reliability of the test. Materials and Methods From June 2021 to February 2023, for the 10 items in which the reagent was changed, the monthly percentage and standard deviation index before and after the reagent change were compared, respectively. At this time, the reference value was arbitrarily set for the comparison group in consideration of the reference value of the test item, and the groups were subdivided and compared, and the standard deviation index allowed range was -2.0 or more and 2.0 or less. Results For CA19-9, CA15-3, AFP, CEA, and calcitonin 5 test items, the change in monthly ratio in all test sections before and after the reagent change was kept constant. On the other hand, for CA72-4, PSA, testosterone, PTH, and estradiol items, the standard deviation index exceeded the acceptable standard after changing the reagent. CA72-4 test items showed an increasing trend in standard deviation index in the test section exceeding the reference value. In the case of the PSA test item, the maintenance ratio of 0.04 ng/mL was significantly decreased after changing the reagent. The testosterone test item had a standard deviation index of -2.5 in the test section exceeding 10.1 ng/mL after changing the reagent, and the standard deviation index of the PTH test item was out of the acceptable range in all test sections. It was confirmed that the estradiol test item showed an overall increase in the result value. Conclusion Through this study, the continuity and accuracy of the test results could be verified. It is considered that the stability of the test can be secured by analyzing the factors affecting the test result and solving the cause for the test item whose standard deviation index is out of the acceptable standard.

• Journal of Acupuncture Research
• /
• 제23권3호
• /
• pp.1-19
• /
• 2006

Objectives : This study was carried out to determine the effects of Gamidokwalgisaeng-tang(GDS) oral administration and electro-acupuncture at $BL_{52}$ & $GB_{39}$ on the postmenopausal osteoporosis. Methods: In order to study the effects of the Gamidokwalgisaeng-tang(GDS) oral administration and electro-acupuncture at $BL_{52}$, $GB_{39}$ on osteoporotic rats induced by ovariectomy, body weight, femur weight, uterine weight, serum level of osteocalcin, alkaline phosphatase(ALP), cholesterol, triglyceride, estradiol, androstenedione, testosterone and urinary excretions of calcium & phosphorus were measured. Results : 1. Body weight in all experimental group decreased significantly in comparison with ovariectomized group(OVX). 2. The weight of femur compared with body increased significantly in GDS oral administration and combination treatment group in comparison with ovariectomized group(OVX). 3. Uterine endometrial morphology is caused by ovariectomy and the weight of uterus decreased significantly in control and all experimental group in comparison with sham. 4. The serum level of osteocalcin decreased in all experimental group in comparison with OVX, but significantly in electro-acupuncture and combination treatment group. 5. The serum alkaline phosphatase(ALP) activity decreased in electro-acupuncture and combination treatment group in comparison with OVX, but only significantly in electro-acupuncture group. 6. The serum level of cholesterol increased significantly in OVX in comparison with sham and decreased in all experimental group in comparison with OVX, not insignificantly. The serum level of triglyceride increased in all experimental group in comparison with OVX, not insignificantly. 7. Urinary excretions of calcium and phosphorus decreased significantly in all experimental group in comparison with OVX. Conclusion : We suggest that GDS oral administration and electro-acupuncture at $BL_{52}$ & $GB_{39}$ are available for prevention and curing about the postmenopausal osteoporosis.